According to a poster presentation at the 2022 AAD annual meeting, patients with psoriatic arthritis (PsA) with high skin burden experienced improved health-related quality of life (HRQoL), including fatigue and pain, at 24 weeks when treated with risankizumab.

“[PsA] greatly affects patient-reported [HRQoL],” explained the study authors. “This analysis integrated efficacy data from two Phase III clinical trials (KEEPsAKE-1 and KEEPsAKE-2) to assess the impact of risankizumab on patient-reported outcomes (PROs) in patients with high skin burden.”

For the study, researchers examined adult patients with PsA who had inadequate response or intolerance to disease-modifying antirheumatic drugs. The study participants were randomized 1:1 to receive either risankizumab or placebo.

Patients with high skin burden—defined as body surface area involvement ≥3% and Psoriasis Area Severity Index >10—were assessed at week 24 of the study. The following PROs were included:

• Patient’s Global Assessment of Disease Activity [PtGA] by visual analog scale [VAS];
• Short-Form 36 Health Questionnaire physical and mental component summary scores [SF-36 PCS and MCS];
• Health Assessment Questionnaire–Disability Index [HAQ-DI];
• EQ-5D 5-Level questionnaire [EQ-5D-5L] index and by VAS;
• Functional Assessment of Chronic Illness Therapy–Fatigue [FACIT-Fatigue]; and
• pain by VAS.

Of note, the least squares mean (LSM) difference (95% confidence interval [CI]) between treatment groups that were reported were based on mixed-model repeated measures regression.

“Risankizumab- vs placebo-treated patients demonstrated greater improvements in PROs with notable LSM differences (95% CI) between groups (P<0.01) in PtGA (-18.7 [-25.1, -12.2]), SF-36 PCS (6.3 [4.2, 8.4]) and MCS (4.4 [2.3, 6.6]), HAQ-DI (-0.4 [-0.5, -0.3]), EQ-5D-5L index (0.1 [0.1, 0.2]) and VAS (8.2 [2.5,13.9]), FACIT-Fatigue (4.9 [2.7, 7.2]), and pain ( 18.9 [-25.1, -12.7]),” wrote the study authors.

Reference:

Papp K, Soliman AM, Kaufmann C, et al. Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from two Phase III trials. Presented at: AAD Annual Meeting; March 25-28, 2022; Boston, MA.